EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Metabolic Improvements in Women With and Without Polyendocrine Metabolic Syndrome via a Multidisciplinary Telehealth Care Platform

Heather G Huddleston iD, Rachel Blank, Nandita Sommers, Nicole Hellman, Felice Ramallo, Tiffany Pham, Karla Lindquist iD

Endocrinology, Diabetes & Metabolism · 2026

DOI: 10.1002/edm2.70332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2026. Verfasst von Heather G Huddleston und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Metabolic Syndrome, Polycystic Ovary Syndrome. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate metabolic outcomes in women with and without Polyendocrine Metabolic Ovarian Syndrome (PMOS, formerly Polycystic Ovary Syndrome (PCOS))) receiving multidisciplinary care through a women's health telehealth platform that combines physician and registered dietitian support.

Methods

Retrospective cohort analysis of 919 women with BMI ≥ 25 initiating care in 2024, with ≥ 6 months follow‐up (mean 9.6 months). Participants included 557 with PMOS and 362 without. Outcomes extracted from the electronic health record (EHR) included change in weight, HbA1c, HOMA‐IR, fasting insulin, fasting glucose, ALT, AST and total cholesterol between baseline and last measured value. Linear regression models adjusted for baseline values of each outcome, age, BMI, race/ethnicity and follow‐up time.

Results

Significant improvements were observed across all metabolic markers for the group overall: HOMA‐IR (−14.0%), fasting insulin (−15.6%), fasting glucose (−13.0%), HbA1c (−6.2%), ALT (−21.2%), AST (−25.5%), total cholesterol (−8.0%) and weight (−4.9%). PCOS status was not associated with differential improvement in any outcome after adjustment. GLP‐1 receptor agonist use was associated with greater weight loss; however, improvements were also observed in the no‐medication group.

Conclusions

Women with PCOS achieved metabolic improvements equivalent to those without PMOS through a multidisciplinary telehealth model despite presenting with a more adverse metabolic profile at baseline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromePolycystic Ovary SyndromeHumansFemaleTelemedicineRetrospective StudiesAdultBlood GlucoseGlycated HemoglobinInsulin ResistanceInsulin

Substanzen

Blood GlucoseGlycated HemoglobinInsulin

Autor:innen und Institutionen

  • Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California, USA.
  • Allara Health, New York, New York, USA.

ORCID-Profile: Heather G Huddleston, Karla Lindquist

Zitieren

APA

Huddleston, H. G., Blank, R., Sommers, N., Hellman, N., Ramallo, F., Pham, T., & Lindquist, K. (2026). Real‐World Metabolic Improvements in Women With and Without Polyendocrine Metabolic Syndrome via a Multidisciplinary Telehealth Care Platform. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70332

Vancouver

Huddleston HG, Blank R, Sommers N, Hellman N, Ramallo F, Pham T, et al. Real‐World Metabolic Improvements in Women With and Without Polyendocrine Metabolic Syndrome via a Multidisciplinary Telehealth Care Platform. Endocrinology, Diabetes & Metabolism. 2026. doi:10.1002/edm2.70332

BibTeX
@article{Huddleston2026,
  author = {Huddleston, Heather G and Blank, Rachel and Sommers, Nandita and Hellman, Nicole and Ramallo, Felice and Pham, Tiffany and Lindquist, Karla},
  title = {Real‐World Metabolic Improvements in Women With and Without Polyendocrine Metabolic Syndrome via a Multidisciplinary Telehealth Care Platform},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2026},
  doi = {10.1002/edm2.70332}
}
Kostenlos starten →